From Texas Emerging Fund;
Oncolix, Inc. – Common Stock
Intended outcome: Commercialization of Prolanta™, a prolactin receptor antagonist that will block prolactin
receptors found in breast and ovarian cancer patients.
Actual Outcome: The company has an FDA Investigational New Drug clearance to commence human testing
of Prolanta™ in the treatment of ovarian cancer. The FDA has granted Prolanta™ orphan drug status for
ovarian cancer, which may allow an accelerated regulatory FDA approval. In addition to ovarian cancer,
there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers. Oncolix
continues to work with MD Anderson Cancer Center under a sponsored research agreement. In 2014,
research conducted by MD Anderson was published in Cell Reports, which included data to support the
novel mechanism of action of Prolanta™. The company also raised additional bridge loans to support the
ongoing development of Prolanta™, which includes up to $1M participation by the Texas Emerging
Technology Fund. Oncolix completed its Series A financing subsequent to the date of the report.
